Dual-action Pt(Ⅳ) prodrugs and targeted delivery in metal-organic frameworks : overcoming cisplatin resistance and improving anticancer activity
国立国会図書館館内限定公開
収録元データベースで確認する
国立国会図書館デジタルコレクション
デジタルデータあり
公開元のウェブサイトで確認する
DOI[10.1246/bcsj.20220218]のデータに遷移します
全国の図書館の所蔵
国立国会図書館以外の全国の図書館の所蔵状況を表示します。
所蔵のある図書館から取寄せることが可能かなど、資料の利用方法は、ご自身が利用されるお近くの図書館へご相談ください
書誌情報
この資料の詳細や典拠（同じ主題の資料を指すキーワード、著者名）等を確認できます。
- 資料種別
- 記事
- 著者・編者
- Larasati LarasatiWitri Wahyu LestariMaulidan Firdaus
- 出版年月日等
- 2022-11-15
- 出版年（W3CDTF）
- 2022-11-15
- タイトル（掲載誌）
- Bulletin of the Chemical Society of Japan
- 巻号年月日等（掲載誌）
- 95(11)
- 掲載巻
- 95(11)
- ISSN（掲載誌）
- 1348-0634
- ISSN-L（掲載誌）
- 0009-2673
- 本文の言語コード
- eng
- DOI
- 10.1246/bcsj.20220218
- 国立国会図書館永続的識別子
- info:ndljp/pid/12686461
- コレクション（共通）
- コレクション（障害者向け資料：レベル1）
- コレクション（個別）
- 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > 学術機関 > 学協会
- 収集根拠
- オンライン資料収集制度
- 受理日（W3CDTF）
- 2023-03-07T17:43:09+09:00
- 保存日（W3CDTF）
- 2023-01-20
- 記録形式（IMT）
- application/pdf
- オンライン閲覧公開範囲
- 国立国会図書館内限定公開
- デジタル化資料送信
- 図書館・個人送信対象外
- 遠隔複写可否（NDL）
- 可
- 掲載誌（国立国会図書館永続的識別子）
- info:ndljp/pid/12686459
- 連携機関・データベース
- 国立国会図書館 : 国立国会図書館デジタルコレクション
- 要約等
- コレクション : 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > 学術機関 > 学協会
- DOI
- 10.1246/bcsj.20220218
- 関連情報（URI）
- 参照
- Liquid–Liquid and Liquid–Solid Interfacial NanoarchitectonicsBio-gel nanoarchitectonics in tissue engineeringInterface-interactive nanoarchitectonics: solid and/or liquidMaterials Nanoarchitectonics: Collaboration between Chem, Nano and MatRecent Advancements in Novel Sensing Systems through NanoarchitectonicsDisease Diagnosis with Chemosensing, Artificial Intelligence, and Prospective Contributions of NanoarchitectonicsLayered nanoarchitectonics for condensed hard matter, soft matter, and living matterNanoarchitectonics: the method for everything in materials science
- 参照
- Postsynthetic Modifications of Iron-Carboxylate Nanoscale Metal−Organic Frameworks for Imaging and Drug DeliveryAssessment of the Evolution of Cancer Treatment TherapiesA Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against CancerSynthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatinValidating Metal‐Organic Framework Nanoparticles for Their Nanosafety in Diverse Biomedical ApplicationsFe-MIL-101 exhibits selective cytotoxicity and inhibition of angiogenesis in ovarian cancer cells via downregulation of MMPMechanistic Investigation into the Selective Anticancer Cytotoxicity and Immune System Response of Surface-Functionalized, Dichloroacetate-Loaded, UiO-66 NanoparticlesApplications of Metal-Organic Frameworks as Drug Delivery SystemsConjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a “joint action” mode toward DNAPreparation of cisplatin using microwave heating and continuous-flow processing as toolsNanoscale metal–organic frameworks for drug delivery: a conventional platform with new promiseRational design of anticancer platinum(IV) prodrugsMetal-organic frameworks for advanced drug deliveryThe Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating AgentsAn Entry to Novel Platinum Complexes: Carboxylation of Dihydroxoplatinum(IV) Complexes with Succinic Anhydride and Subsequent DerivatizationCytotoxicity of nanoscaled metal–organic frameworksConjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin ResistanceThe ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cellsTargeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrateSelf-stabilized Pt(IV) amphiphiles by precise regulation of branch length for enhanced chemotherapyRecent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugsUnderstanding the diversity of the metal-organic framework ecosystemStimuli-responsive prodrug-based cancer nanomedicineRecent Bio-Advances in Metal-Organic FrameworksMulti-action Pt(IV) anticancer agents; do we understand how they work?Metal organic frameworks: an effective application in drug delivery systemsToward Green Production of Water-Stable Metal–Organic Frameworks Based on High-Valence Metals with Low ToxicitiesBioengineering of Metal-organic Frameworks for NanomedicineDecoration of Cisplatin on 2D Metal–Organic Frameworks for Enhanced Anticancer Effects through Highly Increased Reactive Oxygen Species GenerationPt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistanceCisplatin resistance and opportunities for precision medicineMetal–Organic Frameworks as Efficient Materials for Drug DeliveryRecent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of actionRecent Trends in <i>In Situ</i> Enzyme-Activatable Prodrugs for Targeted Cancer TherapyAn Unusual Route to Potential Platinum Antitumor Compounds: Synthesis, Reactivity, and Spectroscopic Properties of the Pt<sup>IV</sup>Complex<i>fac</i>‐[PtCl<sub>3</sub>(NH<sub>3</sub>)<sub>2</sub>L]ClATP‐Responsive Aptamer‐Based Metal–Organic Framework Nanoparticles (NMOFs) for the Controlled Release of Loads and DrugsA Review of Biomaterials and Their Applications in Drug DeliveryChemotherapy Treatment and Strategy Schemes: A ReviewBiocompatible Zr-based nanoscale MOFs coated with modified poly(ε-caprolactone) as anticancer drug carriersPlatinum(IV) antitumor complexes and their nano-drug deliveryHistone deacetylase inhibitor based prodrugs<p>Recent Progress of Nanoscale Metal-Organic Frameworks in Cancer Theranostics and the Challenges of Their Clinical Application</p>Metal-organic frameworks for stimuli-responsive drug deliveryCatalytic properties of pristine and defect-engineered Zr-MOF-808 metal organic frameworksUnprecedented one-pot synthesis of an unsymmetrical cisplatin-based Pt(<scp>iv</scp>)–acetamidato complexIncreasing the Stability of Metal-Organic FrameworksAnti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of CancerSynthesis Methods and Crystallization of MOFsProspective of nanoscale metal organic frameworks [NMOFs] for cancer therapyTrastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cellsReview on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of CisplatinChlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivoBreakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instabilityWhat blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectivesNew NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivoDNA Damage Induced by Alkylating Agents and Repair PathwaysProdrug strategy for cancer cell-specific targeting: A recent overviewPlatinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effectSynthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agentsPt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cellsOxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial PositionModulation of ligand fluorescence by the Pt(II)/Pt(IV) redox coupleRecent advances in prodrug-based nanoparticle therapeuticsMetal-organic frameworks-based nanozymes for combined cancer therapyAnti-Inflammatory Drugs as Anticancer Agents<p>Toxicity screening of two prevalent metal organic frameworks for therapeutic use in human lung epithelial cells</p>Facile Preparation of Mono‐, Di‐ and Mixed‐Carboxylato Platinum(IV) Complexes for Versatile Anticancer Prodrug DesignPlatinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cellsA cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancerConjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor VasculatureAsplatin enhances drug efficacy by altering the cellular responseConstruction of Flexible‐on‐Rigid Hybrid‐Phase Metal–Organic Frameworks for Controllable Multi‐Drug DeliveryEdible ligand-metal-organic frameworks: Synthesis, structures, properties and applicationsPlatinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?Synthesis of aspirin-ligated cisplatin derivatives and its slow release study over MIL-101(Fe)Innovative approaches for cancer treatment: current perspectives and new challengesCisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapyAdvanced Ordered Nanoporous MaterialsUpdate of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical ApproachesCarboxylation of Dihydroxoplatinum(IV) Complexes via a New Synthetic PathwayThe Discovery and Development of CisplatinBiochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug ResistanceCisplatin: a review of toxicities and therapeutic applicationsThe rediscovery of platinum-based cancer therapyRedox‐Active Metal Complexes for Anticancer TherapyMetal–Organic Framework Nanocarriers for Drug Delivery in Biomedical ApplicationsPt(IV) complexes as prodrugs for cisplatinNSAID’s and selectively COX-2 inhibitors as potential chemoprotective agents against cancerPlatinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclustersA Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: A Dual-Acting Weapon for Targeting DNA in Cancer CellsRecent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and EfficacyBiocompatibility and biodegradability of metal organic frameworks for biomedical applicationsDual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistanceCisplatin-modified isonicotinic acid as a potential linker in bio-MOFs: synthesis and characterizationHarnessing chemoselective imine ligation for tethering bioactive molecules to platinum(iv) prodrugsIncorporation of cisplatin into the metal–organic frameworks UiO66-NH<sub>2</sub> and UiO66 – encapsulation vs. conjugationPt(<scp>iv</scp>) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of actionThe Prodrug Platin‐<i>A</i>: Simultaneous Release of Cisplatin and AspirinCisplatin uptake and release in pH sensitive zeolitic imidazole frameworksMetal-Organic Frameworks (MOFs)-Based Nanomaterials for Drug DeliveryPt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cellsMicrowave-assisted synthesis of nano Hf- and Zr-based metal-organic frameworks for enhancement of curcumin adsorptionProdrugs for targeted cancer therapyEmerging platinum(<scp>iv</scp>) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironmentCurrent Developments in Pt(IV) Prodrugs Conjugated with Bioactive LigandsTriple action Pt(<scp>iv</scp>) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistanceEffective loading of cisplatin into a nanoscale UiO-66 metal–organic framework with preformed defectsPt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulatorsCisplatin in the Treatment of CancerThe side effects of platinum-based chemotherapy drugs: a review for chemistsPlatinum Compounds: a New Class of Potent Antitumour AgentsMicrotubules and Their Role in Cellular Stress in CancerGlobal Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesMetal–organic frameworks as potential drug carriersNanoscale Coordination Polymers for Platinum-Based Anticancer Drug DeliveryCancer statistics, 2020Nanoscale Metal–Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer CellsMechanisms of resistance to cisplatin and carboplatinCarboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor AgentsMetal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer TherapyBiotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistanceSynthesis of Metal-Organic Frameworks (MOFs): Routes to Various MOF Topologies, Morphologies, and CompositesCisplatin: The first metal based anticancer drugSynthesis and Characterization of Platinum(IV) Anticancer Drugs with Functionalized Aromatic Carboxylate Ligands: Influence of the Ligands on Drug Efficacies and UptakeCisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and ToxicityRole of glutathione <i>S</i> -transferase P1-1 in the cellular detoxification of cisplatinSynthetic Methods for the Preparation of Platinum Anticancer ComplexesMetal–Organic Framework Materials with Ultrahigh Surface Areas: Is the Sky the Limit?The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsCisplatin in cancer therapy: Molecular mechanisms of actionToxicity of nanoscale metal organic frameworks: a perspectiveWhat do we know about the reduction of Pt(IV) pro-drugs?Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsPlatinum(IV) antitumour compounds: their bioinorganic chemistrySynthesis of metal-organic frameworks: A mini reviewNanoscale Metal–Organic Frameworks for Cancer ImmunotherapyToward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?Cancer and Radiation Therapy: Current Advances and Future DirectionsOctahedral complexes of anti-cancer Pt(IV)(cyclohexyldiamine) agents with 9-methylguanine
- 連携機関・データベース
- 国立情報学研究所 : CiNii Research
- 提供元機関・データベース
- 雑誌記事索引データベースCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossref
- 書誌ID（NDLBibID）
- 12686461